INKEF Capital
Finance · Netherlands · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gustav Mahlerplein, Amsterdam, North Hol...Phone Number
+31 207946060Website
www.inkefcapital.comRevenue
<$5 MillionIndustry
About INKEF Capital
Is INKEF Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at INKEF Capital
Earning: See what the market has to say on INKEF Capital recently announced quarterly report
Check if INKEF Capital has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
INKEF Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once INKEF Capital has new funding data
Product Launch: Get notified when INKEF Capital launches new products
Check out if INKEF Capital is spiking on competitors!
Click to see if INKEF Capital had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at INKEF Capital
Find 2 more new buyers
Company Profile Activity
Activity Insights
INKEF Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
INKEF Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about INKEF Capital.
INKEF Capital Tech Stack
A closer look at the technologies used by INKEF Capital
Most Recent Scoops
INKEF Capital News & Media
NMD Pharma Raises €75M in Series B Financing
NMD Pharma, an Aarhus, Denmark-based clinical-stage biotechnology company for neuromuscular diseases, raised €75M in Series B funding. The round was led by Jeito Capital and included investments from other current investors Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund. Led by CEO Thomas Holm Pedersen, NMD Pharma is a clinical-stage biotech company […] The post NMD Pharma Raises €75M in Series B Financing appeared first on FinSMEs.Syncona appoints managing partner
Syncona appoints managing partner Submitted 05/04/2023 - 11:38am Syncona Ltd, a healthcare investment company focused on the life sciences sector, has appointed Roel Bulthuis as managing partner and head of investments. Bulthuis has over 20 years of life science venture capital, business development and investment banking experience. Bulthuis joins from Inkef Capital, an Amsterdam-based venture capital firm, where he held the position of managing partner and head of healthcare. Before this, he sQurAlis Closes $88M Series B Financing
QurAlis, a Cambridge, MA-based clinical-stage biotechnology company, raised $88M in Series B funding. The round, which brought the total funds raised to $143.5M, was led by EQT Life Sciences, Sanofi Ventures, and Droia Ventures, with participation from the ALS Investment Fund and existing investors LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen […] The post QurAlis Closes $88M Series B Financing appeared first on FinSMEs.Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
BRUSSELS, March 16, 2022 /PRNewswire/ -- Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads....
Top Finance Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INKEF Capital
INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology companies. INKEF Capital was founded in 2010 by Dutch pension fund ABP and with €500 million under management is one of the largest venture capital funds in the Netherlands. INKEF focuses on investment opportu... Read More